Peripheral neuropathy in patients using GLP-1 receptor agonists: emerging clinical concerns
Abstract
Background: Glucagon-like peptide-1 receptor agonists have become widely used in the management of diabetes mellitus and obesity due to their efficacy in glycemic control and weight reduction. Although generally considered safe, the rapid metabolic and weight changes associated with these agents have raised questions regarding potential neurological effects. Objective: To analyze current evidence regarding the possible association between glucagon-like peptide-1 receptor agonist therapy and the development or worsening of peripheral neuropathy. Methods: A structured search of recent studies and clinical reports indexed in PubMed was performed. Publications describing neurological symptoms, peripheral nerve dysfunction, and metabolic alterations associated with glucagon-like peptide-1 receptor agonists were identified and qualitatively analyzed. Results: Available evidence suggests that while glucagon-like peptide-1 receptor agonists may have anti-inflammatory and neuroprotective properties, some reports describe the occurrence or worsening of neuropathic symptoms in certain patients during treatment. Proposed mechanisms include rapid weight loss, metabolic shifts, and potential nutritional deficiencies that may contribute to peripheral nerve dysfunction. Additionally, metabolic changes affecting glucose variability and micronutrient balance may play a role in the development of neuropathic manifestations. Conclusion: Although glucagon-like peptide-1 receptor agonists remain effective therapies for metabolic diseases, clinicians should remain aware of possible neurological symptoms during treatment. Further clinical studies are needed to clarify the relationship between these agents and peripheral neuropathy and to identify patients at potential risk.